Is BMS The Must Have Immuno-Oncology Accessory Of The Season?

 
• By Lucie Ellis-Taitt

Bristol-Myers Squibb is in the M&A hot seat, and Pfizer could be the one applying fire.

Chalkboard
Is Pfizer after BMS's immuno-oncology pipeline? • Source: Shutterstock

More from Strategy

More from Business